All
Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
Understanding Genetic and Genomic Testing in Breast Cancer
Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.
Investigating Quality of Life and Treatment Adherence in Kidney Cancer
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Life Lessons I Learned After My Colon Cancer Diagnosis
After being diagnosed with colon cancer, I learned the life-changing lessons of self-love, stepping out of my comfort zone and embracing positive thinking.
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
First Patient Dosed in Trial for Chemotherapy-Induced Neuropathic Pain
The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.
The Importance of Spotting Endometrial Cancer
Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
First relapse in multiple myeloma: the patient perspective
The Role of Circulating Tumor DNA in Breast Cancer Monitoring
Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.
Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.
Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia
Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.
A Picture is Worth Ten Thousand Words When it Comes to Cancer
Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.
Precision Radiation Therapy Makes Strides in Colorectal Cancer Care
Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel treatment for the disease.
SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds
Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.
Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
Why It’s Important to Have Hard Conversations in Breast Cancer Care
CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.
Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.
Jelmyto Maintains Effectiveness Over Time in Bladder Cancer Subtype
Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.
PSMA-PET Improves Detection of Metastases in High-Risk Prostate Cancer
Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by conventional imaging.
Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease
Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month.
Triple-Positive Breast Cancer Research Saved My Daughter’s Life
Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved from cancer.
Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer
Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in high-risk bladder cancer.
Longer Imbruvica and Venclexta Treatment May Be Beneficial in R/R CLL
For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found to be beneficial.
Antihistamines Associated With Bladder Cancer Survival, Progression Improvements
Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.
Trusting My Stage 4 Breast Cancer Body
Practicing consistency has made a difference for me while living with stage 4 breast cancer.
ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.
